Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

98 comunicati stampa

Guarda tutti i comunicati
31/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
31/07/2026
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
24/07/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
29/06/2026
Oncologia
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Industria
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
26/06/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
28/05/2026
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/05/2026
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/05/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Mercato del lavoro
Industria
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
11/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0